Emergent Initiates Quality Enhancement Plan For Troubled Baltimore Vaccine Facility

• Emergent BioSolutions Inc (NYSE: EBS) has been in headlines after its Baltimore plant has drawn the scrutiny of the FDA.

• A manufacturing mix-up ruined 15 million Johnson & Johnson (NYSE: JNJ) COVID-19 vaccine doses at the Baltimore plant.

• Last month, the FDA completed its inspection of the troubled vaccine manufacturing plant and released a couple of blistering observations on the cross-contamination, sanitary issues, and lack of staff training.

• Today, Emergent responded to FDA’s observations with a comprehensive quality enhancement plan.

• Emergent said it has already started making improvements and is committed to making the necessary short and long-term enhancements to meet or exceed FDA’s standards.

• The company is continuing into an ongoing dialogue with the FDA and Johnson & Johnson to resume production.

• Price Action: EBS shares are trading 1.3% higher at $59.55 during the market session on the last check Wednesday.

See more from Benzinga

• Click here for options trades from Benzinga

• FDA Outlines Plan For Restarting Facility Inspections Halted Due To Pandemic

• FDA To Hold AdCom Meeting For Expanding Use COVID-19 Vaccine In Children

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.